New combo therapy for High-Risk breast cancer enters safety testing
NCT ID NCT07446686
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial will test the safety and tolerability of combining a CDK4/6 inhibitor (abemaciclib) with radiation therapy after surgery in 30 women with HR+/HER2- high-risk breast cancer. The study aims to find the highest safe dose of the drug when used alongside radiation and standard hormone therapy. Researchers will also track patients' quality of life using questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CDK4/6 inhibitor (abemaciclib) plus endocrine therapy
- What this could lead to
- If successful, this could show that combining CDK4/6 inhibitors with radiotherapy after surgery is safe and tolerable for high-risk breast cancer patients.
- What could go wrong
- This is a very early, small trial (30 people) focused only on safety and dosing. It cannot yet prove whether the combination works better than standard care, and side effects may be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?